Crizotinib-induced acute fatal liver failure in an Asian ALK-positive lung adenocarcinoma patient with liver metastasis: A case report

Figure 1 Computed tomography indicated mediastinal and hepatic metastatic changes. A: Chest computed tomography (CT) showed a 8.4 × 9.8 cm mediastinal metastatic lump; B: Chest CT on day 35 showed a slight shrink in mediastinal metastasis; C: Chest CT on day 55 showed unchanged mediastinal lump compared to B; D: Abdominal CT showed multiple metastases; E: Liver metastasis slightly shrank after 35 d of crizotinib therapy; F: Liver volume increased by 20% and acute intrahepatic bile were revealed on day 55.

Figure 2 Detailed changes of liver enzymes during crizotinib therapy (day 1–55) and after crizotinib discontinuation (day 56–59). A: Upper graph: aspartate aminotransferase and alanine aminotransferase; B: Lower graph: total bilirubin and prothrombin time. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; PT: Prothrombin time.